The outlook of companies tied to the drug's history presents a complex investment landscape. While the initial boom generated substantial gains, generic copies have significantly eroded revenue. Investing in related pharmaceutical businesses now requires a discerning assessment of proprietary protection , evolving medical trends , and the potential